Edition:
United States

Imprimis Pharmaceuticals Inc (IMMY.OQ)

IMMY.OQ on NASDAQ Stock Exchange Capital Market

2.20USD
23 Apr 2018
Change (% chg)

$-0.05 (-2.22%)
Prev Close
$2.25
Open
$2.24
Day's High
$2.25
Day's Low
$2.14
Volume
9,762
Avg. Vol
67,693
52-wk High
$4.54
52-wk Low
$1.35

Select another date:

Tue, Mar 27 2018

BRIEF-Imprimis Pharmaceuticals Issued Composition Patent For Non-Opioid Conscious Sedation Formulation

* IMPRIMIS PHARMACEUTICALS ISSUED COMPOSITION PATENT FOR NON-OPIOID CONSCIOUS SEDATION FORMULATION

BRIEF-Imprimis Pharmaceuticals Q4 Revenue $7.3 Million

* IMPRIMIS PHARMACEUTICALS ANNOUNCES FOURTH QUARTER 2017 RESULTS

BRIEF-Imprimis Pharma Makes Available Two Glaucoma Drugs On FDA's Drug Shortage List

* IMPRIMIS PHARMACEUTICALS NOW MAKING AVAILABLE TWO GLAUCOMA DRUGS ON FDA'S DRUG SHORTAGE LIST Source text for Eikon: Further company coverage:

BRIEF-Imprimis Pharmaceuticals Is Issued DEA Manufacturer Certificate For Its 503B Outsourcing Facility

* IMPRIMIS PHARMACEUTICALS IS ISSUED DEA MANUFACTURER CERTIFICATE FOR ITS 503B OUTSOURCING FACILITY Source text for Eikon: Further company coverage:

Imprimis receives FDA warning over eye medication advertising

Jan 16 The U.S. Food and Drug Administration has issued a warning letter to Imprimis Pharmaceuticals Inc accusing it of making false or misleading claims that its compounded eye medications had the agency's approval.

Allergan may pursue lawsuit against drug compounder Imprimis

Allergan PLC can proceed with a false advertising lawsuit seeking to stop Imprimis Pharmaceuticals Inc from selling compounded drugs that bypass regulatory approval, including a cheaper alternative to Allergan's dry eye drug, Restasis, a federal judge has ruled.

BRIEF-Imprimis Pharmaceuticals Q3 loss per share $‍0.28​

* Imprimis Pharmaceuticals announces third quarter 2017 results

Select another date: